Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kamada Ltd KMDA

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune... see more

Recent & Breaking News (NDAQ:KMDA)

Kamada Appoints Senior Biopharmaceutical Executive Michal Ayalon, Ph.D., as Vice President of Research and Development

GlobeNewswire January 30, 2019

Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018

GlobeNewswire January 2, 2019

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Benzinga.com  December 30, 2018

Kamada Reports Financial Results for Third Quarter and First Nine Months of 2018

GlobeNewswire November 12, 2018

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12

GlobeNewswire November 5, 2018

Kamada Announces Appointment of Life Sciences Industry Executive Eitan Kyiet as Vice President of Business Development

GlobeNewswire October 22, 2018

Kamada to Present Corporate Overview at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 25, 2018

Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation

GlobeNewswire September 5, 2018

Kamada Provides Updated Full-Year 2018 Revenue Guidance

GlobeNewswire August 29, 2018

Cannabics Pharmaceuticals Inc. Appoints Dr. Estery Giloz-Ran to Its Advisory Board

PR Newswire August 28, 2018

Kamada Announces the End of the Labor Strike in the Company’s Manufacturing Facility; All Employees Returned to Work

GlobeNewswire August 16, 2018

Kamada Reports Financial Results for Second Quarter and First Six Months of 2018

GlobeNewswire August 7, 2018

Kamada to Announce Second Quarter and Six Months Ended June 30, 2018 Financial Results and Host Conference Call on August 7

GlobeNewswire August 1, 2018

Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT

GlobeNewswire July 10, 2018

Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

GlobeNewswire June 4, 2018

Kamada Reports Financial Results for First Quarter of 2018

GlobeNewswire May 15, 2018

Kamada Ltd to Host Earnings Call

Accesswire May 15, 2018

Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15

GlobeNewswire May 9, 2018

Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

Business Wire May 8, 2018

Israel-Based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

PR Newswire Europe Non Regulatory April 25, 2018